


WHAT IS CLAIMED:

1. A compound of Formula (I):



5

(I)

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

the lactam ring of Formula (I) is substituted with 0-2 R^b;

10

X is selected from the group: B(OH)₂, BY¹Y², and

C(=O)C(=O)NHR^{1a};

15 Y¹ and Y² are independently selected from:

- a) -OH,
- b) -F,
- c) -NR¹⁸R¹⁹,
- d) C₁-C₈ alkoxy, or

when taken together, Y¹ and Y² form:

20

- e) a cyclic boron ester comprising from 2 to 20 carbon atoms, and, optionally, 1, 2, or 3 heteroatoms which can be N, S, or O;
- f) a cyclic boron amide comprising from 2 to 20 carbon atoms and, optionally, 1, 2, or 3 heteroatoms which can be N, S, or O; or
- 25 g) a cyclic boron amide-ester comprising from 2 to 20 carbon atoms and, optionally, 1, 2, or 3 heteroatoms which can be N, S, or O;

25

30 R¹ is selected from the group:

C₁₋₁₀ alkyl substituted with 0-3 R^a;

C₂₋₁₀ alkenyl substituted with 0-3 R^a;

C₂₋₁₀ alkynyl substituted with 0-3 R^a; and

C₃₋₆ cycloalkyl substituted with 0-3 R^a;

10010204-20
10010204-21
10010204-22
10010204-23
10010204-24
10010204-25
10010204-26
10010204-27
10010204-28
10010204-29
10010204-30
10010204-31
10010204-32
10010204-33
10010204-34
10010204-35
10010204-36
10010204-37
10010204-38
10010204-39
10010204-40
10010204-41
10010204-42
10010204-43
10010204-44
10010204-45
10010204-46
10010204-47
10010204-48
10010204-49
10010204-50
10010204-51
10010204-52
10010204-53
10010204-54
10010204-55
10010204-56
10010204-57
10010204-58
10010204-59
10010204-60
10010204-61
10010204-62
10010204-63
10010204-64
10010204-65
10010204-66
10010204-67
10010204-68
10010204-69
10010204-70
10010204-71
10010204-72
10010204-73
10010204-74
10010204-75
10010204-76
10010204-77
10010204-78
10010204-79
10010204-80
10010204-81
10010204-82
10010204-83
10010204-84
10010204-85
10010204-86
10010204-87
10010204-88
10010204-89
10010204-90
10010204-91
10010204-92
10010204-93
10010204-94
10010204-95
10010204-96
10010204-97
10010204-98
10010204-99
10010204-100
10010204-101
10010204-102
10010204-103
10010204-104
10010204-105
10010204-106
10010204-107
10010204-108
10010204-109
10010204-110
10010204-111
10010204-112
10010204-113
10010204-114
10010204-115
10010204-116
10010204-117
10010204-118
10010204-119
10010204-120
10010204-121
10010204-122
10010204-123
10010204-124
10010204-125
10010204-126
10010204-127
10010204-128
10010204-129
10010204-130
10010204-131
10010204-132
10010204-133
10010204-134
10010204-135
10010204-136
10010204-137
10010204-138
10010204-139
10010204-140
10010204-141
10010204-142
10010204-143
10010204-144
10010204-145
10010204-146
10010204-147
10010204-148
10010204-149
10010204-150
10010204-151
10010204-152
10010204-153
10010204-154
10010204-155
10010204-156
10010204-157
10010204-158
10010204-159
10010204-160
10010204-161
10010204-162
10010204-163
10010204-164
10010204-165
10010204-166
10010204-167
10010204-168
10010204-169
10010204-170
10010204-171
10010204-172
10010204-173
10010204-174
10010204-175
10010204-176
10010204-177
10010204-178
10010204-179
10010204-180
10010204-181
10010204-182
10010204-183
10010204-184
10010204-185
10010204-186
10010204-187
10010204-188
10010204-189
10010204-190
10010204-191
10010204-192
10010204-193
10010204-194
10010204-195
10010204-196
10010204-197
10010204-198
10010204-199
10010204-200
10010204-201
10010204-202
10010204-203
10010204-204
10010204-205
10010204-206
10010204-207
10010204-208
10010204-209
10010204-210
10010204-211
10010204-212
10010204-213
10010204-214
10010204-215
10010204-216
10010204-217
10010204-218
10010204-219
10010204-220
10010204-221
10010204-222
10010204-223
10010204-224
10010204-225
10010204-226
10010204-227
10010204-228
10010204-229
10010204-230
10010204-231
10010204-232
10010204-233
10010204-234
10010204-235
10010204-236
10010204-237
10010204-238
10010204-239
10010204-240
10010204-241
10010204-242
10010204-243
10010204-244
10010204-245
10010204-246
10010204-247
10010204-248
10010204-249
10010204-250
10010204-251
10010204-252
10010204-253
10010204-254
10010204-255
10010204-256
10010204-257
10010204-258
10010204-259
10010204-260
10010204-261
10010204-262
10010204-263
10010204-264
10010204-265
10010204-266
10010204-267
10010204-268
10010204-269
10010204-270
10010204-271
10010204-272
10010204-273
10010204-274
10010204-275
10010204-276
10010204-277
10010204-278
10010204-279
10010204-280
10010204-281
10010204-282
10010204-283
10010204-284
10010204-285
10010204-286
10010204-287
10010204-288
10010204-289
10010204-290
10010204-291
10010204-292
10010204-293
10010204-294
10010204-295
10010204-296
10010204-297
10010204-298
10010204-299
10010204-300
10010204-301
10010204-302
10010204-303
10010204-304
10010204-305
10010204-306
10010204-307
10010204-308
10010204-309
10010204-310
10010204-311
10010204-312
10010204-313
10010204-314
10010204-315
10010204-316
10010204-317
10010204-318
10010204-319
10010204-320
10010204-321
10010204-322
10010204-323
10010204-324
10010204-325
10010204-326
10010204-327
10010204-328
10010204-329
10010204-330
10010204-331
10010204-332
10010204-333
10010204-334
10010204-335
10010204-336
10010204-337
10010204-338
10010204-339
10010204-340
10010204-341
10010204-342
10010204-343
10010204-344
10010204-345
10010204-346
10010204-347
10010204-348
10010204-349
10010204-350
10010204-351
10010204-352
10010204-353
10010204-354
10010204-355
10010204-356
10010204-357
10010204-358
10010204-359
10010204-360
10010204-361
10010204-362
10010204-363
10010204-364
10010204-365
10010204-366
10010204-367
10010204-368
10010204-369
10010204-370
10010204-371
10010204-372
10010204-373
10010204-374
10010204-375
10010204-376
10010204-377
10010204-378
10010204-379
10010204-380
10010204-381
10010204-382
10010204-383
10010204-384
10010204-385
10010204-386
10010204-387
10010204-388
10010204-389
10010204-390
10010204-391
10010204-392
10010204-393
10010204-394
10010204-395
10010204-396
10010204-397
10010204-398
10010204-399
10010204-400
10010204-401
10010204-402
10010204-403
10010204-404
10010204-405
10010204-406
10010204-407
10010204-408
10010204-409
10010204-410
10010204-411
10010204-412
10010204-413
10010204-414
10010204-415
10010204-416
10010204-417
10010204-418
10010204-419
10010204-420
10010204-421
10010204-422
10010204-423
10010204-424
10010204-425
10010204-426
10010204-427
10010204-428
10010204-429
10010204-430
10010204-431
10010204-432
10010204-433
10010204-434
10010204-435
10010204-436
10010204-437
10010204-438
10010204-439
10010204-440
10010204-441
10010204-442
10010204-443
10010204-444
10010204-445
10010204-446
10010204-447
10010204-448
10010204-449
10010204-450
10010204-451
10010204-452
10010204-453
10010204-454
10010204-455
10010204-456
10010204-457
10010204-458
10010204-459
10010204-460
10010204-461
10010204-462
10010204-463
10010204-464
10010204-465
10010204-466
10010204-467
10010204-468
10010204-469
10010204-470
10010204-471
10010204-472
10010204-473
10010204-474
10010204-475
10010204-476
10010204-477
10010204-478
10010204-479
10010204-480
10010204-481
10010204-482
10010204-483
10010204-484
10010204-485
10010204-486
10010204-487
10010204-488
10010204-489
10010204-490
10010204-491
10010204-492
10010204-493
10010204-494
10010204-495
10010204-496
10010204-497
10010204-498
10010204-499
10010204-500
10010204-501
10010204-502
10010204-503
10010204-504
10010204-505
10010204-506
10010204-507
10010204-508
10010204-509
10010204-510
10010204-511
10010204-512
10010204-513
10010204-514
10010204-515
10010204-516
10010204-517
10010204-518
10010204-519
10010204-520
10010204-521
10010204-522
10010204-523
10010204-524
10010204-525
10010204-526
10010204-527
10010204-528
10010204-529
10010204-530
10010204-531
10010204-532
10010204-533
10010204-534
10010204-535
10010204-536
10010204-537
10010204-538
10010204-539
10010204-540
10010204-541
10010204-542
10010204-543
10010204-544
10010204-545
10010204-546
10010204-547
10010204-548
10010204-549
10010204-550
10010204-551
10010204-552
10010204-553
10010204-554
10010204-555
10010204-556
10010204-557
10010204-558
10010204-559
10010204-560
10010204-561
10010204-562
10010204-563
10010204-564
10010204-565
10010204-566
10010204-567
10010204-568
10010204-569
10010204-570
10010204-571
10010204-572
10010204-573
10010204-574
10010204-575
10010204-576
10010204-577
10010204-578
10010204-579
10010204-580
10010204-581
10010204-582
10010204-583
10010204-584
10010204-585
10010204-586
10010204-587
10010204-588
10010204-589
10010204-590
10010204-591
10010204-592
10010204-593
10010204-594
10010204-595
10010204-596
10010204-597
10010204-598
10010204-599
10010204-600
10010204-601
10010204-602
10010204-603
10010204-604
10010204-605
10010204-606
10010204-607
10010204-608
10010204-609
10010204-610
10010204-611
10010204-612
10010204-613
10010204-614
10010204-615
10010204-616
10010204-617
10010204-618
10010204-619
10010204-620
10010204-621
10010204-622
10010204-623
10010204-624
10010204-625
10010204-626
10010204-627
10010204-628
10010204-629
10010204-630
10010204-631
10010204-632
10010204-633
10010204-634
10010204-635
10010204-636
10010204-637
10010204-638
10010204-639
10010204-640
10010204-641
10010204-642
10010204-643
10010204-644
10010204-645
10010204-646
10010204-647
10010204-648
10010204-649
10010204-650
10010204-651
10010204-652
10010204-653
10010204-654
10010204-655
10010204-656
10010204-657
10010204-658
10010204-659
10010204-660
10010204-661
10010204-662
10010204-663
10010204-664
10010204-665
10010204-666
10010204-667
10010204-668
10010204-669
10010204-670
10010204-671
10010204-672
10010204-673
10010204-674
10010204-675
10010204-676
10010204-677
10010204-678
10010204-679
10010204-680
10010204-681
10010204-682
10010204-683
10010204-684
10010204-685
10010204-686
10010204-687
10010204-688
10010204-689
10010204-690
10010204-691
10010204-692
10010204-693
10010204-694
10010204-695
10010204-696
10010204-697
10010204-698
10010204-699
10010204-700
10010204-701
10010204-702
10010204-703
10010204-704
10010204-705
10010204-706
10010204-707
10010204-708
10010204-709
10010204-710
10010204-711
10010204-712
10010204-713
10010204-714
10010204-715
10010204-716
10010204-717
10010204-718
10010204-719
10010204-720
10010204-721
10010204-722
10010204-723
10010204-724
10010204-725
10010204-726
10010204-727
10010204-728
10010204-729
10010204-730
10010204-731
1

10010131-120502

R^{1a} is selected from the group:

C₁₋₁₀ alkyl substituted with 0-3 R^a;

C₂₋₁₀ alkenyl substituted with 0-3 R^a;

5 C₂₋₁₀ alkynyl substituted with 0-3 R^a; and

C₃₋₆ cycloalkyl substituted with 0-3 R^a;

R^a is selected at each occurrence from the group:

C₁₋₃ alkyl, C₃₋₆ cycloalkyl, Cl, F, Br, I, CF₃, OH, =O,

10 C₁₋₆ alkoxy, SH, -S-C₁₋₆ alkyl;

phenyl substituted with 0-3 R^b;

naphthyl substituted with 0-3 R^b;

-O-(CH₂)_q-phenyl substituted with 0-3 R^b;

-O-(CH₂)_q-naphthyl substituted with 0-3 R^b; and

15 5-10 membered heteroaryl consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and substituted with 0-3 R^b;

R^b is selected at each occurrence from the group:

20 C₁₋₆ alkyl, Cl, F, Br, I, OH, C₁₋₆ alkoxy, -CN, -NO₂,

C(O)OR⁷, NR^dRD, CF₃, OCF₃, and C₃₋₆ cycloalkyl;

R² is H;

25 alternatively, R¹ and R² combine to form a C₃₋₅ cycloalkyl group;

R³ is selected from the group:

C₁₋₆ alkyl substituted with 0-2 R^a;

30 C₂₋₆ alkenyl substituted with 0-2 R^a;

C₂₋₆ alkynyl substituted with 0-2 R^a;

- (CH₂)_q-C₃₋₆ cycloalkyl substituted with 0-2 R^a;

- (CH₂)_q-phenyl substituted with 0-2 R^a;

- (CH₂)_q-naphthyl substituted with 0-2 R^a; and

- $(CH_2)_q$ -5-10 membered heteroaryl consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and substituted with 0-2 R^a;

5 R⁴ is selected from the group: H,
C₁₋₆ alkyl substituted with 0-3 R^b;
phenyl substituted with 0-3 R^b;
benzyl substituted with 0-3 R^b; and
phenethyl substituted with 0-3 R^b;

10

R⁵ is H or Q-R^{5a};

Q is 0, 1, 2, or 3 amino acids;

15 R^{5a} is selected from the group: -S(O)R⁶, -S(O)₂R⁶, -C(O)R⁶,
-C(O)OR⁸, -C(O)NHR⁶, C₁₋₃ alkyl-R^{6a}, C₂₋₆ alkenyl-R^{6a},
and C₂₋₆ alkynyl-R^{6a};

R⁶ is selected from the group:

20 C₁₋₆ alkyl substituted with 0-3 R^c;
phenyl substituted with 0-3 R^c;
naphthyl substituted with 0-3 R^c;
benzyl substituted with 0-3 R^c; and
5-10 membered heteroaryl consisting of carbon atoms
25 and 1-4 heteroatoms selected from the group: O, S, and
N, substituted with 0-3 R^c;

R^{6a} is selected from the group:

30 phenyl substituted with 0-3 R^c;
naphthyl substituted with 0-3 R^c;
benzyl substituted with 0-3 R^c; and
5-10 membered heteroaryl consisting of carbon atoms
and 1-4 heteroatoms selected from the group: O, S, and
N, substituted with 0-3 R^c;

35

100-000000-120000
R^c is selected at each occurrence from the group:

C₁₋₄ alkyl, C₁₋₄ alkoxy, CF₃, OCF₃, Cl, F, Br, I, =O,
OH, phenyl, C(O)OR⁷, NR^dR^d, -CN, and NO₂;

5 R^d is selected at each occurrence from the group: H and
CH₃;

10 R⁷ is selected at each occurrence from the group: H and C₁₋₆ alkyl;


15 R⁸ is selected from the group: C₁₋₆ alkyl, benzyl, and C₃₋₆ cycloalkyl-methyl;

20 R¹⁸ and R¹⁹ at each occurrence are independently selected
from H, C_{1-C4} alkyl, aryl(C_{1-C4} alkyl)-, and C_{3-C7} cycloalkyl;

n is selected from the group: 1, 2, and 3; and

25 q is selected from the group: 0, 1, and 2.

2. A compound according to Claim 1 of Formula (I):



25 or a stereoisomer or pharmaceutically acceptable salt form
thereof, wherein;

the lactam ring of Formula (I) is substituted with 0-2 R^b;

30 X is selected from the group: B(OH)₂, BY¹Y², and
C(=O)C(=O)NHR^{1a};

Y¹ and Y² are independently selected from:

a) -OH,

10010184-120601
b) -F,
c) -NR¹⁸R¹⁹,
d) C₁-C₈ alkoxy, or

when taken together, Y¹ and Y² form:

5 e) a cyclic boron ester comprising from 2 to 20 carbon atoms, and, optionally, 1, 2, or 3 heteroatoms which can be N, S, or O;

10 f) a cyclic boron amide comprising from 2 to 20 carbon atoms and, optionally, 1, 2, or 3 heteroatoms which can be N, S, or O; or

15 g) a cyclic boron amide-ester comprising from 2 to 20 carbon atoms and, optionally, 1, 2, or 3 heteroatoms which can be N, S, or O;

15 R¹ is selected from the group:

C₁-6 alkyl substituted with 0-3 R^a;
C₂-6 alkenyl substituted with 0-3 R^a;
C₂-6 alkynyl substituted with 0-3 R^a; and
C₃-6 cycloalkyl substituted with 0-3 R^a;

20 R^{1a} is selected from the group:

C₁-10 alkyl substituted with 0-3 R^a;
C₂-10 alkenyl substituted with 0-3 R^a;
C₂-10 alkynyl substituted with 0-3 R^a; and
25 C₃-6 cycloalkyl substituted with 0-3 R^a;

R^a is selected at each occurrence from the group:

30 C₁-3 alkyl, C₃-6 cycloalkyl, Cl, F, Br, I, CF₃, OH, =O,
C₁-6 alkoxy, SH, -S-C₁-6 alkyl;
phenyl substituted with 0-3 R^b;
naphthyl substituted with 0-3 R^b;
-O-(CH₂)_q-phenyl substituted with 0-3 R^b;
-O-(CH₂)_q-naphthyl substituted with 0-3 R^b; and

5-10 membered heteroaryl consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and substituted with 0-3 R^b;

5 R^b is selected at each occurrence from the group:
C₁₋₆ alkyl, Cl, F, Br, I, OH, C₁₋₆ alkoxy, -CN, -NO₂, C(O)OR⁷, NR^dR^d, CF₃, OCF₃, and C₃₋₆ cycloalkyl;

R² is H;

10 alternatively, R¹ and R² combine to form a C₃₋₅ cycloalkyl group;

R³ is selected from the group:

15 C₁₋₆ alkyl substituted with 0-2 R^a;
C₂₋₆ alkenyl substituted with 0-2 R^a;
C₂₋₆ alkynyl substituted with 0-2 R^a;
-(CH₂)_q-C₃₋₆ cycloalkyl substituted with 0-2 R^a;
-(CH₂)_q-phenyl substituted with 0-2 R^a;
20 -(CH₂)_q-naphthyl substituted with 0-2 R^a; and
-(CH₂)_q-5-10 membered heteroaryl consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and substituted with 0-2 R^a;

25 R⁴ is selected from the group: H,
C₁₋₆ alkyl substituted with 0-3 R^b;
phenyl substituted with 0-3 R^b;
benzyl substituted with 0-3 R^b; and
phenethyl substituted with 0-3 R^b;

30 R⁵ is H or Q-R^{5a};

Q is 0, 1, 2, or 3 amino acids;

R^{5a} is selected from the group: $-S(O)R^6$, $-S(O)_2R^6$, $-C(O)R^6$, $-C(O)OR^8$, $-C(O)NHR^6$, C_{1-3} alkyl- R^{6a} , C_{2-6} alkenyl- R^{6a} , and C_{2-6} alkynyl- R^{6a} ;

5 R⁶ is selected from the group:

C₁₋₆ alkyl substituted with 0-3 R^c;

phenyl substituted with 0-3 R^c;

naphthyl substituted with 0-3 R^c;

benzyl substituted with 0-3 R^c; and

10 5-10 membered heteroaryl consisting of carbon atoms
and 1-4 heteroatoms selected from the group: O, S, and
N, substituted with 0-3 R^c;

R^{6a} is selected from the group:

15 phenyl substituted with 0-3 R^c;
naphthyl substituted with 0-3 R^c;
benzyl substituted with 0-3 R^c; and
5-10 membered heteroaryl consisting of carbon atoms
and 1-4 heteroatoms selected from the group: O, S, and
20 N, substituted with 0-3 R^c;

R^c is selected at each occurrence from the group:

C₁₋₄ alkyl, C₁₋₄ alkoxy, CF₃, OCF₃, Cl, F, Br, I, =O,

OH, phenyl, $\text{C}(\text{O})\text{OR}^7$, $\text{NR}^{\text{d}}\text{R}^{\text{d}}$, -CN, and NO_2 ;

25 R^d is selected at each occurrence from the group: H and
CH₃.

R^7 is selected at each occurrence from the group: H and C_1 -
 α -alkyl:


R⁸ is selected from the group: C₁₋₆ alkyl, benzyl, and C₃₋₆ cycloalkyl-methyl:

R¹⁸ and R¹⁹ at each occurrence are independently selected from H, C₁-C₄ alkyl, aryl(C₁-C₄ alkyl)-, and C₃-C₇ cycloalkyl;

5 n is selected from the group: 1, 2, and 3; and

q is selected from the group: 0, 1, and 2.

3. A compound according to Claim 2 of Formula (I):



or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

15 the lactam ring of Formula (I) is substituted with 0-2 R^b;

X is selected from the group: B(OH)₂ and BY¹Y²;

Y¹ and Y² are independently selected from:

20 a) -OH,

b) C₁-C₈ alkoxy, or

when taken together, Y¹ and Y² form:

c) a cyclic boron ester comprising from 2 to 20 carbon atoms;

25

R¹ is selected from the group:

C₁-6 alkyl substituted with 0-3 halogen; and

C₂-6 alkenyl substituted with 0-3 halogen;

30 R^a is selected at each occurrence from the group:

C₁-3 alkyl, C₃-6 cycloalkyl, Cl, F, Br, I, CF₃, OH, =O,

C₁-6 alkoxy, SH, -S-C₁-6 alkyl;

phenyl substituted with 0-3 R^b;

naphthyl substituted with 0-3 R^b;

-O- $(\text{CH}_2)_q$ -phenyl substituted with 0-3 R^b;
-O- $(\text{CH}_2)_q$ -naphthyl substituted with 0-3 R^b; and
5-10 membered heteroaryl consisting of carbon atoms
and 1-4 heteroatoms selected from the group: O, S, and
5 N, and substituted with 0-3 R^b;

R^b is selected at each occurrence from the group:
 C_{1-6} alkyl, Cl, F, Br, I, OH, C_{1-6} alkoxy, -CN, -NO₂,
 $C(O)OR^7$, NR^dR^d , CF₃, OCF₃, and C_{3-6} cycloalkyl;

10

R^3 is selected from the group:
C₁₋₆ alkyl substituted with 0-2 R^a;
C₂₋₆ alkenyl substituted with 0-2 R^a;
C₂₋₆ alkynyl substituted with 0-2 R^a;
-(CH₂)_q-C₃₋₆ cycloalkyl substituted with 0-2 R^a;
-(CH₂)_q-phenyl substituted with 0-2 R^a;
-(CH₂)_q-naphthyl substituted with 0-2 R^a; and
-(CH₂)_q-5-10 membered heteroaryl consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and substituted with 0-2 R^a;

R^4 is selected from the group: H,
 C_{1-6} alkyl substituted with 0-3 R^b ;
phenyl substituted with 0-3 R^b ;
benzyl substituted with 0-3 R^b ; and
phenethyl substituted with 0-3 R^b ;

30 R⁵ is H or O-R^{5a}:

Q is 0, 1, 2, or 3 amino acids;

R^{5a} is selected from the group: $-S(O)R^6$, $-S(O)_2R^6$, $-C(O)R^6$, $-C(O)OR^8$, $-C(O)NHR^6$, C_{1-3} alkyl- R^{6a} , C_{2-6} alkenyl- R^{6a} , and C_{2-6} alkynyl- R^{6a} ;

5 R⁶ is selected from the group:

C₁₋₆ alkyl substituted with 0-3 R^c;

phenyl substituted with 0-3 R^c;

naphthyl substituted with 0-3 R^c;

benzyl substituted with 0-3 R^c; and

10 5-10 membered heteroaryl consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, substituted with 0-3 R^c;

R^{6a} is selected from the group:

15 phenyl substituted with 0-3 R^c;
naphthyl substituted with 0-3 R^c;
benzyl substituted with 0-3 R^c; and
5-10 membered heteroaryl consisting of carbon atoms
and 1-4 heteroatoms selected from the group: O, S, and
20 N, substituted with 0-3 R^c;

R^c is selected at each occurrence from the group:

C₁₋₄ alkyl, C₁₋₄ alkoxy, CF₃, OCF₃, Cl, F, Br, I, =O, OH, phenyl, C(O)OR⁷, NR^dRD, -CN, and NO₂;

25 R^d is selected at each occurrence from the group: H and
 G


R⁷ is selected at each occurrence from the group: H and C₁-30 alkyl.

R⁸ is selected from the group: C₁₋₆ alkyl, benzyl, and C₃₋₆ cycloalkyl-methyl:

35 n is selected from the group: 1, 2, and 3; and

q is selected from the group: 0, 1, and 2.

4. A compound according to Claim 3, wherein the compound
5 is of Formula (II):



or a stereoisomer or pharmaceutically acceptable salt form
thereof, wherein:

10

X is a boronic acid or a boron ester of formula BY¹Y²;

Y¹ and Y² are independently selected from:

a) C₁-C₆ alkoxy, or

15

when taken together, Y¹ and Y² form:

b) a cyclic boron ester comprising from 2 to 16 carbon
atoms;

20

R¹ is selected from the group: ethyl, n-propyl, n-butyl,
allyl, 2,2,2-trifluoroethyl, 2,2-difluoroethyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, and 3-butenyl;

R^a is selected at each occurrence from the group:

C₁₋₃ alkyl, C₃₋₆ cycloalkyl, Cl, F, Br, I, CF₃, OH, =O,

25

C₁₋₆ alkoxy, SH, -S-C₁₋₆ alkyl;

phenyl substituted with 0-3 R^b;

naphthyl substituted with 0-3 R^b;

-O-(CH₂)_q-phenyl substituted with 0-3 R^b;

-O-(CH₂)_q-naphthyl substituted with 0-3 R^b; and

30

5-10 membered heteroaryl consisting of carbon atoms
and 1-4 heteroatoms selected from the group: O, S, and
N, and substituted with 0-3 R^b;

R^b is selected at each occurrence from the group:

C₁₋₆ alkyl, Cl, F, Br, I, OH, C₁₋₆ alkoxy, -CN, -NO₂, C(O)OR⁷, NR^dR^d, CF₃, OCF₃, and C₃₋₆ cycloalkyl;

R² is H;

5

R³ is selected from the group:

C₁₋₆ alkyl substituted with 0-2 R^a;

C₂₋₆ alkenyl substituted with 0-2 R^a;

C₂₋₆ alkynyl substituted with 0-2 R^a;

10 - (CH₂)_q-C₃₋₆ cycloalkyl substituted with 0-2 R^a;

- (CH₂)_q-phenyl substituted with 0-2 R^a;

- (CH₂)_q-naphthyl substituted with 0-2 R^a;

15 - (CH₂)_q-5-10 membered heteroaryl consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, and substituted with 0-2 R^a;

R⁴ is selected from the group: H, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl; phenyl substituted with 0-3 R^b;

20 benzyl substituted with 0-3 R^b; and phenethyl substituted with 0-3 R^b;

R⁵ is H or Q-R^{5a};

25 Q is 0, 1, or 2 amino acids;

R^{5a} is selected from the group: -S(O)R⁶, -S(O)₂R⁶, -C(O)R⁶, -C(O)OR⁸, -C(O)NHR⁶, C₁₋₃ alkyl-R^{6a}, C₂₋₆ alkenyl-R^{6a}, and C₂₋₆ alkynyl-R^{6a};

30

R⁶ is selected from the group:

C₁₋₆ alkyl substituted with 0-3 R^c;

phenyl substituted with 0-3 R^c;

naphthyl substituted with 0-3 R^c;

35 benzyl substituted with 0-3 R^c; and

5-10 membered heteroaryl consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, substituted with 0-3 R^c;

5 R^{6a} is selected from the group:

phenyl substituted with 0-3 R^c;

naphthyl substituted with 0-3 R^c;

benzyl substituted with 0-3 R^c; and

10 5-10 membered heteroaryl consisting of carbon atoms and 1-4 heteroatoms selected from the group: O, S, and N, substituted with 0-3 R^c;

R^c is selected at each occurrence from the group:

C₁₋₄ alkyl, C₁₋₄ alkoxy, CF₃, OCF₃, Cl, F, Br, I, =O,

15 OH, phenyl, C(O)OR⁷, NR^dRD, -CN, and NO₂;

R^d is selected at each occurrence from the group: H and CH₃;


20 R⁷ is selected at each occurrence from the group: H and C₁₋₆ alkyl;

R⁸ is selected from the group: C₁₋₆ alkyl, benzyl, and C₃₋₆ cycloalkyl-methyl;

25 n is 1 or 2; and

q is selected from the group: 0, 1, and 2.

30 5. A compound according to Claim 4, wherein the compound is of Formula (II):



(III)

phenyl substituted with 0-3 R^c;
naphthyl substituted with 0-3 R^c;
benzyl substituted with 0-3 R^c; and
quinolinyl substituted with 0-3 R^c;

5

R^{6a} is selected from the group:

phenyl substituted with 0-3 R^c;
naphthyl substituted with 0-3 R^c;
benzyl substituted with 0-3 R^c; and
10 quinolinyl substituted with 0-3 R^c;

10

R^c is selected at each occurrence from the group:

methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl,
t-butyl, methoxy, ethoxy, propoxy, i-propoxy, CF₃,
15 OCF₃, Cl, F, Br, I, OH, phenyl, C(O)OH, NH₂, -CN, and
NO₂;

15


R⁸ is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl,
t-butyl, phenyl, and benzyl; and
20

20

n is 1 or 2.

6. A compound according to Claim 4, wherein the compound
is of Formula (II):

25



(II)

or a stereoisomer or pharmaceutically acceptable salt form
thereof, wherein;

30 X is a boronic acid or a boron ester of formula BY¹Y²;

Y¹ and Y² are individually selected from C₁-C₆ alkoxy, or
when taken together, Y¹ and Y² form a cyclic boron

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

5 X is a boronic acid or boron ester, wherein the ester is a diol selected from the group: pinanediol, pinacol, 1,2-ethanediol, 1,3-propanediol, 1,2-propanediol, 2,3-butanediol, 1,2-diisopropylethanediol, 5,6-decanediol, and 1,2-dicyclohexylethanediol;

10 R¹ is selected from the group: ethyl, n-propyl, n-butyl, allyl, 2,2,2-trifluoroethyl, 2,2-difluoroethyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, and 3-butenyl;

15 R² is H;

15 R³ is selected from the group: n-propyl, n-butyl, i-butyl, n-pentyl, neo-pentyl, cyclohexylmethyl, cyclopentylmethyl, phenyl, t-butoxymethyl, benzylloxymethyl, hydroxymethyl, methoxymethyl, 20 ethoxymethyl, propoxymethyl, and i-propoxymethyl;

25 R⁴ is selected from the group: methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, phenyl, benzyl, and phenethyl;

25 R⁵ is H or Q-R^{5a};

Q is 0, 1, or 2 amino acids;

30 R^{5a} is selected from the group: -S(O)₂R⁶, -C(O)R⁶, -C(O)OR⁸, -C(O)NHR⁶, and -CH₂-R^{6a};

35 R⁶ is selected from the group:
methyl substituted with 0-3 R^c;
ethyl substituted with 0-3 R^c;
propyl substituted with 0-3 R^c;
butyl substituted with 0-3 R^c;

ester where said chain or ring contains from 2 to 14 carbon atoms;

5 R¹ is selected from the group: ethyl, n-propyl, n-butyl, allyl, 2,2,2-trifluoroethyl, 2,2-difluoroethyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, and 3-butenyl;

R² is H;

10 R³ is selected from the group: i-butyl, neo-pentyl, cyclohexylmethyl, t-butoxymethyl, benzyloxymethyl, hydroxymethyl, and phenyl;

15 R⁴ is selected from the group: ethyl, n-propyl, i-propyl, R-2-butyl, S-2-butyl, phenyl, benzyl, and phenethyl;

20 R⁵ is selected from the group: H, benzyl, m-methylphenylsulfonyl, m-trifluoromethylphenylsulfonyl, p-i-propylphenylsulfonyl, p-propylphenylsulfonyl, p-t-butylphenylsulfonyl, p-carboxylphenylsulfonyl, 4-(1,1')biphenylsulfonyl, 1-naphthylsulfonyl, 2-naphthylsulfonyl, 8-quinolinylsulfonyl, pyrazin-2-ylcarbonyl, n-butylsulfonyl, N-phenylaminocarbonyl, N-(p-n-butylphenyl)aminocarbonyl, benzyloxycarbonyl, methoxycarbonyl, t-butyloxycarbonyl, benzoyl, methanesulfonyl,

phenylsulfonyl,
o-nitrophenylsulfonyl,
m-nitrophenylsulfonyl, and
m-aminophenylsulfonyl; and

5

n is 1 or 2.

7. A compound according to Claim 6, wherein;

10 X is a boronic acid or boron ester, wherein the ester is a
diol selected from the group: pinanediol, pinacol,
1,2-ethanediol, 1,3-propanediol, 1,2-propanediol, 2,3-
butanediol, 1,2-diisopropylethanediol, 5,6-decanediol,
and 1,2-dicyclohexylethanediol;

15

R¹ is selected from the group: ethyl, n-propyl, n-butyl,
allyl, 2,2,2-trifluoroethyl, 2,2-difluoroethyl, 3,3,3-
trifluoropropyl, 4,4,4-trifluorobutyl, and 3-butenyl;

20 R² is H;

R³ is selected from the group: i-butyl, neo-pentyl,
cyclohexylmethyl, t-butoxymethyl, benzyloxymethyl,
hydroxymethyl, and phenyl;

25

R⁴ is selected from the group: ethyl, n-propyl, i-propyl,
R-2-butyl, S-2-butyl, phenyl, benzyl, and phenethyl;

30

R⁵ is selected from the group: H,
benzyl,
m-methylphenylsulfonyl,
m-trifluoromethylphenylsulfonyl,
p-i-propylphenylsulfonyl,
p-propylphenylsulfonyl,
35 p-t-butylphenylsulfonyl,
p-carboxylphenylsulfonyl,
4-(1,1')biphenylsulfonyl,

1-naphthylsulfonyl,
2-naphthylsulfonyl,
8-quinolinylsulfonyl,
pyrazin-2-ylcarbonyl,
5 n-butylylsulfonyl,
N-phenylaminocarbonyl,
N-(p-n-butylylphenyl)aminocarbonyl,
benzyloxycarbonyl,
methoxycarbonyl,
10 t-butyloxycarbonyl,
benzoyl,
methanesulfonyl,
phenylsulfonyl,
o-nitrophenylsulfonyl,
15 m-nitrophenylsulfonyl, and
m-aminophenylsulfonyl; and

n is 1 or 2.

20 8. A compound according to Claim 1, wherein the compound
is selected from the group:

(1*R*)-1-((2*S*)-3-cyclohexyl-2-(3-isopropyl-3-((2*S*)-3-methyl-2-((2-pyrazinylcarbonyl)amino)butanoyl)amino)-2-oxo-1-pyrrolidinylpropanoyl)amino)-3-butenylboronic acid (+)-pinanediol ester;

(1*R*)-1-((2*S*)-3-cyclohexyl-2-(3-isopropyl-3-((2*S*)-3-methyl-2-((2-pyrazinylcarbonyl)amino)butanoyl)amino)-2-oxo-1-piperidinylpropanoyl)amino)-3-butenylboronic acid (+)-pinanediol ester;

(1*R*)-1-((3-((methylsulfonyl)amino)-2-oxohexahydro-1*H*-azepin-1-yl)acetyl)amino)propylboronic acid (+)-pinanediol ester;

(1*R*)-1-{{(2*S*)-2-(3-amino-3-isopropyl-2-oxo-1-pyrrolidinyl)-3-cyclohexylpropanoyl)amino}propylboronic acid (+)-pinanediol ester hydrochloride;

5 1*R*)-1-(((2*S*)-2-{3-(((1,1'-biphenyl)-4-ylsulfonyl)amino)-3-isopropyl-2-oxo-1-pyrrolidinyl}-3-cyclohexylpropanoyl)amino)propylboronic acid (+)-pinanediol ester;

10 (1*R*)-1-(((2*S*)-3-cyclohexyl-2-(3-isopropyl-2-oxo-3-((4-
propylphenyl)sulfonyl)amino)-1-
pyrrolidinyl)propanoyl)amino)propylboronic acid (+)-
pinanediol ester;

15 (1*R*)-1-(((2*S*)-3-cyclohexyl-2-{3-isopropyl-3-((1-naphthylsulfonyl)amino)-2-oxo-1-pyrrolidinyl}propanoyl)amino)propylboronic acid (+)-pinanediol ester;

20 (1*R*)-1-(((2*S*)-2-{3-((anilinocarbonyl)amino)-3-isopropyl-2-
oxo-1-pyrrolidinyl}-3-
cyclohexylpropanoyl)amino)propylboronic acid (+)-pinanediol
ester;

25 (1*R*)-1-(((2*S*)-3-cyclohexyl-2-(3-isopropyl-3-((3-methylphenyl)sulfonyl)amino)-2-oxo-1-pyrrolidinyl)propanoyl)amino)propylboronic acid (+)-pinanediol ester;

30 (1*R*)-1-(((2*S*)-3-cyclohexyl-2-(3-isopropyl-3-((3-methylphenyl)sulfonyl)amino)-2-oxo-1-pyrrolidinyl)propanoyl)amino}propylboronic acid

35 (1*R*)-1-{{(3-{{(benzyloxy)carbonyl}amino}-3-isopropyl-2-oxo-1-pyrrolidinyl)(phenyl)acetyl}amino}propylboronic acid (+)-pinanediol ester;

(1*R*)-1-{{(3-amino-3-isopropyl-2-oxo-1-pyrrolidinyl)(phenyl)acetyl}amino}propylboronic acid (+)-pinanediol ester hydrochloride;

5 (1*R*)-1-{{(3-isopropyl-3-((methylsulfonyl)amino)-2-oxo-1-pyrrolidinyl)(phenyl)acetyl}amino}propylboronic acid (+)-pinanediol ester;

10 (1*R*)-1-{{(3-isopropyl-2-oxo-3-((4-propylphenyl)sulfonyl)amino)-1-pyrrolidinyl)(phenyl)acetyl}amino}propylboronic acid (+)-pinanediol ester;

15 (1*R*)-1-{{(2*S*)-2-(3-((benzyloxy)carbonyl)amino)-3-isopropyl-2-oxo-1-pyrrolidinyl)-4-methylpentanoyl}amino}propylboronic acid (+)-pinanediol ester;

20 (1*R*)-1-{{(2*S*)-2-(3-amino-3-isopropyl-2-oxo-1-pyrrolidinyl)-4-methylpentanoyl}amino}propylboronic acid (+)-pinanediol ester hydrochloride;

25 (1*R*)-1-{{(2*S*)-2-(3-isopropyl-3-((methylsulfonyl)amino)-2-oxo-1-pyrrolidinyl)-4-methylpentanoyl}amino}propylboronic acid (+)-pinanediol ester;

30 (1*R*)-1-{{(2*S*)-2-(3-isopropyl-2-oxo-3-((4-propylphenyl)sulfonyl)amino)-1-pyrrolidinyl)-4-methylpentanoyl}amino}propylboronic acid (+)-pinanediol ester;

35 (1*R*)-1-{{(2*S*)-3-cyclohexyl-2-(3-ethyl-3-((2*S*)-3-methyl-2-((2-pyrazinylcarbonyl)amino)butanoyl)amino)-2-oxo-1-pyrrolidinyl}propanoyl}amino)-3-but enylboronic acid (+)-pinanediol ester;

(1*R*)-1-{{(2*S*)-2-(3-((benzyloxy)carbonyl)amino)-3-isopropyl-2-oxo-1-piperidinyl)-3-

cyclohexylpropanoyl)amino}propylboronic acid (+)-pinanediol ester;

5 (1*R*)-1-{{3-((tert-butoxycarbonyl)amino)-3-isopropyl-2-oxo-1-piperidinyl}(phenyl)acetyl}amino}propylboronic acid (+)-pinanediol ester;

10 (1*R*)-1-{{(3-amino-3-isopropyl-2-oxo-1-piperidinyl)(phenyl)acetyl}amino}propylboronic acid hydrochloride (+)-pinanediol ester;

15 (1*R*)-1-{{(3-isopropyl-3-((methoxycarbonyl)amino)-2-oxo-1-piperidinyl)(phenyl)acetyl}amino}propylboronic acid (+)-pinanediol ester;

20 (1*R*)-1-{{(3-(benzoylamino)-3-isopropyl-2-oxo-1-piperidinyl)(phenyl)acetyl}amino}propylboronic acid (+)-pinanediol ester;

25 (1*R*)-1-{{(3-isopropyl-3-((methylsulfonyl)amino)-2-oxo-1-piperidinyl)(phenyl)acetyl}amino}propylboronic acid (+)-pinanediol ester; and

30 (1*R*)-1-{{(3-isopropyl-3-{{(3-methylphenyl)sulfonyl}amino}-2-oxo-1-piperidinyl)(phenyl)acetyl}amino}propylboronic acid (+)-pinanediol ester;

or a pharmaceutically acceptable salt form thereof.

35 9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 1 or pharmaceutically acceptable salt form thereof.

40 10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 2 or pharmaceutically acceptable salt form thereof.

11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 3 or
5 pharmaceutically acceptable salt form thereof.

13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 4 or
10 pharmaceutically acceptable salt form thereof.

14. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 5 or
15 pharmaceutically acceptable salt form thereof.

15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 6 or
20 pharmaceutically acceptable salt form thereof.

16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 7 or
25 pharmaceutically acceptable salt form thereof.

17. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 8 or
30 pharmaceutically acceptable salt form thereof.

18. A method of inhibiting HCV NS3 protease which comprises contacting HCV NS3 protease with a therapeutically effective amount of a compound of Claim 1
35 or pharmaceutically acceptable salt form thereof.

19. A method of inhibiting HCV NS3 protease which comprises contacting HCV NS3 protease with a

therapeutically effective amount of a compound of Claim 2 or pharmaceutically acceptable salt form thereof.

20. A method of inhibiting HCV NS3 protease which
5 comprises contacting HCV NS3 protease with a
therapeutically effective amount of a compound of Claim 3 or pharmaceutically acceptable salt form thereof.

21. A method of inhibiting HCV NS3 protease which
10 comprises contacting HCV NS3 protease with a
therapeutically effective amount of a compound of Claim 4 or pharmaceutically acceptable salt form thereof.

22. A method of inhibiting HCV NS3 protease which
15 comprises contacting HCV NS3 protease with a
therapeutically effective amount of a compound of Claim 5 or pharmaceutically acceptable salt form thereof.

23. A method of inhibiting HCV NS3 protease which
20 comprises contacting HCV NS3 protease with a
therapeutically effective amount of a compound of Claim 6 or pharmaceutically acceptable salt form thereof.

24. A method of inhibiting HCV NS3 protease which
25 comprises contacting HCV NS3 protease with a
therapeutically effective amount of a compound of Claim 7 or pharmaceutically acceptable salt form thereof.

25. A method of inhibiting HCV NS3 protease which
30 comprises contacting HCV NS3 protease with a
therapeutically effective amount of a compound of Claim 8 or pharmaceutically acceptable salt form thereof.

26. A method of treating HCV infection which
35 comprises administering to a host in need of such treatment a therapeutically effective amount of a compound of Claim 1 or pharmaceutically acceptable salt form thereof.